Acute Pyelonephritis - Pipeline Insight, 2022

Acute Pyelonephritis - Pipeline Insight, 2022

DelveInsight’s, “Acute Pyelonephritis - Pipeline Insight, 2022,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Acute Pyelonephritis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Acute Pyelonephritis Understanding

Acute Pyelonephritis: Overview

Acute pyelonephritis is a bacterial infection causing inflammation of the kidneys. Pyelonephritis occurs as a complication of an ascending urinary tract infection that spreads from the bladder to the kidneys. Symptoms usually include fever, flank pain, nausea, vomiting, burning with urination, increased frequency, and urgency. The 2 most common symptoms are usually fever and flank pain. Acute pyelonephritis can be divided into uncomplicated and complicated. Complicated pyelonephritis includes pregnant patients, patients with uncontrolled diabetes, kidney transplants, urinary anatomical abnormalities, acute or chronic kidney failure, as well as immunocompromised patients, and those with hospital-acquired bacterial infections.

""Acute Pyelonephritis - Pipeline Insight, 2022"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Acute Pyelonephritis pipeline landscape is provided which includes the disease overview and Acute Pyelonephritis treatment guidelines. The assessment part of the report embraces, in depth Acute Pyelonephritis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
 
Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence in Acute Pyelonephritis R&D. The therapies under development are focused on novel approaches to treat/improve in Acute Pyelonephritis.

This segment of the Acute Pyelonephritis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Acute Pyelonephritis Emerging Drugs

Tebipenem pivoxil: Spero Therapeutics

Spero’s lead product candidate, tebipenem HBr, is being developed as the first oral carbapenem antibiotic for use in complicated urinary tract infection and acute pyelonephritis. In September 2020, tebipenem HBr completed a pivotal Phase III trial, ADAPT-PO, for the treatment of cUTI including acute pyelonephritis (AP). If approved, tebipenem HBr would be the first oral carbapenem antimicrobial to receive marketing approval in the United States. Tebipenem HBr has been granted Qualified Infectious Disease Product (QIDP) and Fast Track designations by the FDA for the treatment of cUTI and Acute Pyelonephritis.

Durlobactam: Entasis Therapeutics

Entasis Therapeutics, a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, reported positive topline results from the company’s multi-national Phase 2 clinical trial of its β-lactamase inhibitor, ETX2514, in combination with sulbactam (the combination referred to as ETX2514SUL) in the treatment of complicated urinary tract infections acute pyelonephritis (kidney infection) in adults and complicated urinary tract infections. The results of the Phase 2 trial support progression of ETX2514SUL into Phase III, an important next step in developing pathogen-targeted products against drug-resistant bacterial infections.

VNRX-5133: VenatoRx Pharmaceuticals

VNRX-5133 is an injectable beta-lactamase inhibitor (BLI) that features selective and potent in vitro activity against both serine- and metallo-beta-lactamases (MBLs), including ESBL, OXA, KPC, NDM, and VIM enzymes. Venatorx believes that VNRX-5133, in a fixed combination with the fourth generation cephalosporin, cefepime, has the potential to provide a valuable broad-spectrum treatment option to meet unmet medical needs in patients with infections due to carbapenem-resistant pathogens including carbapenem-resistant Enterobacteriaceae (CRE) and carbapenem-resistant Pseudomonas aeruginosa (CRPA), suspected polymicrobial infections caused by both gram-negative and gram-positive susceptible pathogens, and engineerable bioterror pathogens such as Burkholderia spp. Venatorx is currently enrolling a Phase III clinical trial of cefepime-taniborbactam in patients with complicated urinary tract infections (cUTIs) including Acute Pyelonephritis. Venatorx believes that taniborbactam, in a fixed combination with the fourth generation cephalosporin, cefepime, has the potential to provide a valuable broad-spectrum treatment option.

Further product details are provided in the report……..

Acute Pyelonephritis: Therapeutic Assessment

This segment of the report provides insights about the different Acute Pyelonephritis drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Acute Pyelonephritis

There are approx. 10+ key companies which are developing the therapies for Acute Pyelonephritis. The companies which have their Acute Pyelonephritis drug candidates in the most advanced stage, i.e. preregistration include, Spero Therapeutics.

Phases

DelveInsight’s report covers around 10+ products under different phases of clinical development like

Late stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Acute Pyelonephritis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral

Parenteral

Intravenous

Subcutaneous

Topical

Molecule Type

Products have been categorized under various Molecule types such as

Monoclonal Antibody

Peptides

Polymer

Small molecule

Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Acute Pyelonephritis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Acute Pyelonephritis therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Acute Pyelonephritis drugs.

Acute Pyelonephritis Report Insights

Acute Pyelonephritis Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

Acute Pyelonephritis Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs
 
Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing Acute Pyelonephritis drugs?

How many Acute Pyelonephritis drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Acute Pyelonephritis?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Acute Pyelonephritis?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Acute Pyelonephritis and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

VenatoRx Pharmaceuticals

Entasis Therapeutics

Paratek Pharmaceuticals

MerLion Pharmaceuticals

Spero Therapeutics

Key Products

VNRX-5133

Durlobactam/sulbactam

Omadacycline

Finafloxacin

Tebipenem pivoxil